Literature DB >> 11732873

Primary natural killer cell lymphoma of the lacrimal sac.

T Mori1, M Tokuhira, S Mori, N Sato, I Miura, A Adachi, H Kuroda, J Tamaru, S Itoyama, H Suzuki, T Abe, T Takeuchi.   

Abstract

Primary lymphoid tumors of the lacrimal sac are quite rare, and all reported cases are of B-cell tumors with good prognosis. To our knowledge, this is the first case of primary natural killer (NK) cell lymphoma of the lacrimal sac. A 55-year-old woman presented with a lacrimal sac tumor, and histological diagnosis of NK cell lymphoma was made. Although disease was initially localized to the right lacrimal sac, it invaded into the adjacent ethmoidal sinus before chemotherapy was initiated (clinical stage IIE). Epstein-Barr virus (EBV)-encoded small RNA (EBER) was detected in lymphoma cells by in situ hybridization. Systemic chemotherapy combined with intrathecal chemotherapy followed by local radiotherapy was performed, and the patient achieved complete remission. However, shortly after completion of chemoradiotherapy, the lymphoma relapsed with rapid systemic dissemination. The disease was refractory to chemotherapy, and the patient eventually succumbed due to sepsis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11732873     DOI: 10.1007/s002770100368

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  2 in total

1.  Primary lymphoma of the lacrimal sac: an EORTC ophthalmic oncology task force study.

Authors:  L D Sjö; E Ralfkiaer; B R Juhl; J U Prause; T Kivelä; C Auw-Haedrich; F Bacin; M Carrera; S E Coupland; B Delbosc; N Ducrey; B Kantelip; J L Kemeny; P Meyer; N C Sjö; S Heegaard
Journal:  Br J Ophthalmol       Date:  2006-05-03       Impact factor: 4.638

2.  Case of primary diffuse large B-cell lymphoma of lacrimal sac in a Japanese patient.

Authors:  Fusae Kajita; Toshiyuki Oshitari; Jiro Yotsukura; Kaoru Asanagi; Takayuki Baba; Takashi Kishimoto; Shuichi Yamamoto
Journal:  Clin Ophthalmol       Date:  2010-11-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.